Is Agilent Technologies, Inc. (A) a Buy, Sell, or Hold?
NYSE : A
Agilent Technologies, Inc.
$138.57 USD
-$1.17 (-0.84%)
- Volume
- 1.13M
- Average Volume
- 2.42M
- Market Capitalization
- $39.14B
- P/E Ratio
- 27.77
- Dividend Yield
- 0.73%
- Price Target
- $152.50
- Year High
- $160.27
- Year Low
- $108.35
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.20
- Current Ratio
- $2.10
Company Overview
NYSE
Padraig McDonnell
Medical - Diagnostics & Research
Healthcare
A
18100
US
USD
Liquidity Metrics
0.47
2.10
1.62
0.80
0.20
Sales & Valuation
$6.95B
5.41
5.51
31.16
4.44
Profitability
$4.57
$1.3B
19.55%
21.85%
20.84%
10.82%
P/E Metrics
27.77
1.23
1.23
Analyst Price Target & Rating
$152.50
$165.00
$140.00
3/5
41 Analysts
-9.13%
Financial Health Scores
5.34
9/9
$2.49B
$13.06B
$5.94B
$1.68B
Key Metrics (TTM)
$40.68B
5.63
20.74
2.10
20.84%
12.54%
3.61%
3.21%
$53.19
127 days
Company Executives
| Name | Title |
|---|---|
| Angelica Riemann | Senior VP & President of Agilent CrossLab Group |
| Frederick Schwarz | Senior VP, Chief Strategy & Corporate Development Officer |
| Meghan A. Henson | Senior Vice President & Chief Human Resources Officer |
| Tim Downs | VP & Chief Accounting Officer |
| Adam S. Elinoff | Senior Vice President, Chief Financial Officer & Principal Financial Officer |
| Michael Buckner | Senior Vice President, Chief Legal Officer, & Secretary |
| Rodney Gonsalves | Vice President of Finance |
| Yvonne Mackie | MD of UK & Ireland Operations and Vice President of Human Resources - Europe |
| August Specht | Senior Vice President & Chief Technology Officer |
| Tejas Rajeev Savant | Vice President of Investor Relations |
| Simon May | Senior VP and President of Life Sciences & Diagnostics Markets Group |
| Padraig McDonnell | Chief Executive Officer, President & Director |
Poll Results
No votes yet today — be the first to share your view!
About Agilent Technologies, Inc. (NYSE:A) Stock
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solut ... ions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
2026-07-23 08:00:00
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD.
Agilent Increases Its Investment in HALO X-ray Technologies
2026-07-20 03:11:00
NOTTINGHAM, England--(BUSINESS WIRE)-- #AgilentTechnologies--Multimillion dollar investment round to enable HALO to complete regulatory approval of its advanced security screening technology.
Dividend Champion, Contender, And Challenger Highlights: Week Of July 19
2026-07-17 23:12:40
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.
2026-07-14 08:00:00
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb'.
Agilent Strengthens Biopharma Growth Prospects With AI Expansion
2026-07-09 14:55:16
A enhances AI-powered lab software, automation and digital workflows to support drug discovery, biopharma research and long-term growth.
2026-07-08 08:00:00
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides.
Alpha and Omega Semiconductor Unveils AmpStack™ Packaging: A Leap Forward in MOSFET Power Density
2026-07-07 11:00:00
[url="]Alpha and Omega Semiconductor Limited[/url] (AOS) (Nasdaq: AOSL), a designer, developer, and global supplier of a broad range of discrete power devices,
Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
2026-07-01 08:00:00
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to.
Frequently Asked Questions
-
What is the current Agilent Technologies, Inc. (A) stock price?
-
Agilent Technologies, Inc.(NYSE:A) stock price is $138.57 in the last trading session. During the trading session, A stock reached the peak price of $160.27 while $108.35 was the lowest point it dropped to. The percentage change in A stock occurred in the recent session was --0.84% while the dollar amount for the price change in A stock was -$1.17.
-
A's industry and sector of operation?
-
The NYSE listed A is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of A?
-
Angelica Riemann | Senior VP & President of Agilent CrossLab Group
Frederick Schwarz | Senior VP, Chief Strategy & Corporate Development Officer
Meghan A. Henson | Senior Vice President & Chief Human Resources Officer
Tim Downs | VP & Chief Accounting Officer
Adam S. Elinoff | Senior Vice President, Chief Financial Officer & Principal Financial Officer -
How many employees does A have?
-
Number of A employees currently stands at 18100. A operates from 5301 Stevens Creek Boulevard, Santa Clara, CA 95051, US.
-
Link for A official website?
-
Official Website of A is: https://www.agilent.com
-
How do I contact A?
-
A could be contacted at phone #800 227 9770 and can also be accessed through its website. A operates from 5301 Stevens Creek Boulevard, Santa Clara, CA 95051, US.
-
How many shares of A are traded daily?
-
The average number of A shares traded daily for last 3 months was 2.42M.
-
What is the market cap of A currently?
-
The market value of A currently stands at $39.14B with its latest stock price at $138.57